Home > Press > Harris & Harris Group Notes $27 Million Financing of Mersana Therapeutics
![]() |
Abstract:
Harris & Harris Group, Inc. (NASDAQ: TINY), an early-stage, active investor in transformative nanotechnology companies, notes the announcement by Mersana Therapeutics, Inc., of the close of a $27 million Series A-1 financing led by a new investor, New Enterprise Associates. Harris & Harris Group invested in this round of financing. Participation in the round also included another new investor, Pfizer Venture Investments, and Mersana's other existing investors, Fidelity Biosciences, ProQuest Investments, and Rho Ventures.
Mersana is a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and its pipeline of small molecule Fleximer conjugates. The proceeds from this financing will be used to advance Mersana's Fleximer-based ADC technology and to generate a pipeline of proprietary next-generation ADCs. The full press release can be viewed at www.prnewswire.com/news-releases/mersana-therapeutics-raises-27m-to-advance-fleximer-antibody-drug-conjugates-164408226.html.
####
About Harris & Harris Group, Inc.
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.prnewswire.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
For more information, please click here
Copyright © Harris & Harris Group, Inc.
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Observing biological nanotransporters: Chemistry April 19th, 2018
Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018
Individual impurity atoms detectable in graphene April 18th, 2018
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018
180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017
180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017
Investments/IPO's/Splits
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018
Nanometrics to Present at the 30th Annual ROTH Conference February 27th, 2018
180 Degree Capital Corp. Reports Net Asset Value per Share of $2.60 as of December 31, 2017; A Decrease of 3.0% From Prior Quarter and an Increase of 11.1% From December 31, 2016 February 27th, 2018
Nanomedicine
Observing biological nanotransporters: Chemistry April 19th, 2018
Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018
Announcements
Observing biological nanotransporters: Chemistry April 19th, 2018
Salt boosts creation of 2-D materials: Rice University scientists show how salt lowers reaction temperatures to make novel materials April 18th, 2018
Individual impurity atoms detectable in graphene April 18th, 2018
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |